The full dataset viewer is not available (click to read why). Only showing a preview of the rows.
Error code: DatasetGenerationError
Exception: CastError
Message: Couldn't cast
longhealth phase 1: struct<n: int64, metric: string, score: double, unparsed: int64, score_parsed: double>
child 0, n: int64
child 1, metric: string
child 2, score: double
child 3, unparsed: int64
child 4, score_parsed: double
_overall: struct<n: int64, metric: string, score: double, unparsed_mcq: int64, unparsed_rate: double>
child 0, n: int64
child 1, metric: string
child 2, score: double
child 3, unparsed_mcq: int64
child 4, unparsed_rate: double
_scorer: struct<commit: string, rules_version: string, scorer_mtime: timestamp[s], scored_at: timestamp[s]>
child 0, commit: string
child 1, rules_version: string
child 2, scorer_mtime: timestamp[s]
child 3, scored_at: timestamp[s]
doc_index: int64
_meta: struct<model: string, mode: string, stream: string, budget: int64, max_new_tokens: int64, phase: int (... 23 chars omitted)
child 0, model: string
child 1, mode: string
child 2, stream: string
child 3, budget: int64
child 4, max_new_tokens: int64
child 5, phase: int64
child 6, n_docs_seen: int64
id: string
read_mode: string
gold: string
category: string
doc: string
generated: string
question: string
to
{'_meta': {'model': Value('string'), 'mode': Value('string'), 'stream': Value('string'), 'budget': Value('int64'), 'max_new_tokens': Value('int64'), 'phase': Value('int64'), 'n_docs_seen': Value('int64')}, 'id': Value('string'), 'category': Value('string'), 'question': Value('string'), 'gold': Value('string'), 'generated': Value('string'), 'doc': Value('string'), 'doc_index': Value('int64'), 'read_mode': Value('string')}
because column names don't match
Traceback: Traceback (most recent call last):
File "/usr/local/lib/python3.14/site-packages/datasets/builder.py", line 1835, in _prepare_split_single
for key, table in generator:
^^^^^^^^^
File "/src/services/worker/src/worker/job_runners/config/parquet_and_info.py", line 621, in wrapped
for item in generator(*args, **kwargs):
~~~~~~~~~^^^^^^^^^^^^^^^^^
File "/usr/local/lib/python3.14/site-packages/datasets/packaged_modules/json/json.py", line 361, in _generate_tables
self._cast_table(pa_table, json_field_paths=json_field_paths),
~~~~~~~~~~~~~~~~^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
File "/usr/local/lib/python3.14/site-packages/datasets/packaged_modules/json/json.py", line 132, in _cast_table
pa_table = table_cast(pa_table, self.info.features.arrow_schema)
File "/usr/local/lib/python3.14/site-packages/datasets/table.py", line 2381, in table_cast
return cast_table_to_schema(table, schema)
File "/usr/local/lib/python3.14/site-packages/datasets/table.py", line 2309, in cast_table_to_schema
raise CastError(
...<3 lines>...
)
datasets.table.CastError: Couldn't cast
longhealth phase 1: struct<n: int64, metric: string, score: double, unparsed: int64, score_parsed: double>
child 0, n: int64
child 1, metric: string
child 2, score: double
child 3, unparsed: int64
child 4, score_parsed: double
_overall: struct<n: int64, metric: string, score: double, unparsed_mcq: int64, unparsed_rate: double>
child 0, n: int64
child 1, metric: string
child 2, score: double
child 3, unparsed_mcq: int64
child 4, unparsed_rate: double
_scorer: struct<commit: string, rules_version: string, scorer_mtime: timestamp[s], scored_at: timestamp[s]>
child 0, commit: string
child 1, rules_version: string
child 2, scorer_mtime: timestamp[s]
child 3, scored_at: timestamp[s]
doc_index: int64
_meta: struct<model: string, mode: string, stream: string, budget: int64, max_new_tokens: int64, phase: int (... 23 chars omitted)
child 0, model: string
child 1, mode: string
child 2, stream: string
child 3, budget: int64
child 4, max_new_tokens: int64
child 5, phase: int64
child 6, n_docs_seen: int64
id: string
read_mode: string
gold: string
category: string
doc: string
generated: string
question: string
to
{'_meta': {'model': Value('string'), 'mode': Value('string'), 'stream': Value('string'), 'budget': Value('int64'), 'max_new_tokens': Value('int64'), 'phase': Value('int64'), 'n_docs_seen': Value('int64')}, 'id': Value('string'), 'category': Value('string'), 'question': Value('string'), 'gold': Value('string'), 'generated': Value('string'), 'doc': Value('string'), 'doc_index': Value('int64'), 'read_mode': Value('string')}
because column names don't match
The above exception was the direct cause of the following exception:
Traceback (most recent call last):
File "/src/services/worker/src/worker/job_runners/config/parquet_and_info.py", line 1379, in compute_config_parquet_and_info_response
parquet_operations, partial, estimated_dataset_info = stream_convert_to_parquet(
~~~~~~~~~~~~~~~~~~~~~~~~~^
builder, max_dataset_size_bytes=max_dataset_size_bytes
^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
)
^
File "/src/services/worker/src/worker/job_runners/config/parquet_and_info.py", line 956, in stream_convert_to_parquet
builder._prepare_split(split_generator=splits_generators[split], file_format="parquet")
~~~~~~~~~~~~~~~~~~~~~~^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
File "/usr/local/lib/python3.14/site-packages/datasets/builder.py", line 1702, in _prepare_split
for job_id, done, content in self._prepare_split_single(
~~~~~~~~~~~~~~~~~~~~~~~~~~^
gen_kwargs=gen_kwargs, job_id=job_id, **_prepare_split_args
^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
):
^
File "/usr/local/lib/python3.14/site-packages/datasets/builder.py", line 1887, in _prepare_split_single
raise DatasetGenerationError("An error occurred while generating the dataset") from e
datasets.exceptions.DatasetGenerationError: An error occurred while generating the datasetNeed help to make the dataset viewer work? Make sure to review how to configure the dataset viewer, and open a discussion for direct support.
_meta dict | id string | category string | question string | gold string | generated string | doc string | doc_index int64 | read_mode string |
|---|---|---|---|---|---|---|---|---|
{
"model": "meta-llama/Llama-3.2-3B-Instruct",
"mode": "recompress",
"stream": "data/streams/longhealth_5phase.json",
"budget": 16384,
"max_new_tokens": 512,
"phase": 4,
"n_docs_seen": 5
} | null | null | null | null | null | null | null | null |
null | patient_01_0 | longhealth_mcq | Which of the following is NOT part of the current treatment regimen for Mrs. Sample's DLBCL?
(a) Polatuzumab vedotin
(b) Rituximab
(c) Cyclophosphamide
(d) Vincristine
(e) Doxorubicin | Vincristine | C. | longhealth phase 1 | 0 | recompress |
null | patient_01_1 | longhealth_mcq | In the context of Mrs. Sample's other diagnoses, which of the following is NOT accurate based on the provided information?
(a) She has 2-vessel disease
(b) She was diagnosed with primary progressive type of multiple sclerosis.
(c) She has a mood disorder.
(d) She has 3-vessel CHD.
(e) She has pre-existing ALS. | She has 3-vessel CHD. | C | longhealth phase 1 | 0 | recompress |
null | patient_01_2 | longhealth_mcq | Which chronic, neuroinflammatory disease does Mrs. Sample suffer from?
(a) Multiple sclerosis
(b) Dementia
(c) Parkinson
(d) Brain abscess
(e) Autoimmune encephalitis | Multiple sclerosis | C | longhealth phase 1 | 0 | recompress |
null | patient_01_3 | longhealth_mcq | Mrs. Sample takes Fingolimod. What is the dosis and when does the patient take it?
(a) 0.5 mg, 1 capsule in the morning
(b) 0.5 mg, 1 capsule at bedtime
(c) 50 mg, 1 capsule in the morning
(d) 35 mg, 1 capsule at bedtime
(e) 70 mg, 1 capsule in the morning | 0.5 mg, 1 capsule at bedtime | C. 50 mg, 1 capsule in the morning | longhealth phase 1 | 0 | recompress |
null | patient_01_4 | longhealth_mcq | Which therapy regime does the oncology board recommend for Mrs. Sample?
(a) 5 cycles of T-Pola-RHP
(b) 7 cycles of R-Luna-CHT
(c) 6 cycles of L-Pola-CRP
(d) 6 cycles of R-Pola-CHP
(e) 8 cycles of M-Pola-CHZ | 6 cycles of R-Pola-CHP | C | longhealth phase 1 | 0 | recompress |
null | patient_01_5 | longhealth_mcq | Mrs. Sample has bone metastasis, of which one was surgically addressed. Where was this metastasis located?
(a) Thoracic vertebra 8
(b) Thoracic vertebra 9
(c) Thoracic vertebra 10
(d) Thoracic vertebra 11
(e) Thoracic vertebra 12 | Thoracic vertebra 10 | C | longhealth phase 1 | 0 | recompress |
null | patient_01_6 | longhealth_mcq | On 01/09/2017, Mrs. Sample received a CT scan of her whole body. What kind of contrast agent was used?
(a) Omnipaque 320
(b) Imeron 400
(c) Optiray 320
(d) Gadovist
(e) Xenetix 350 | Omnipaque 320 | C | longhealth phase 1 | 0 | recompress |
null | patient_01_7 | longhealth_mcq | Mrs. Sample received multiple radiologic examinations. In which order did she receive them?
(a) MR spine > MR Head > CT Thoracic Spine > CT Whole Body
(b) MR Brain > MR thoracic/lumbar spine > CT chest/abdomen/pelvis > CT Thoracic Spine > CT Thoracic Spine > CT chest/abdomen/pelvis > Abdominal ultrasound > MR Spine > ... | MR Brain > MR thoracic/lumbar spine > CT chest/abdomen/pelvis > CT Thoracic Spine > CT Thoracic Spine > CT chest/abdomen/pelvis > Abdominal ultrasound > MR Spine > Whole-body PET/CT > Liver MRI | B. | longhealth phase 1 | 0 | recompress |
null | patient_01_8 | longhealth_mcq | Mrs. Sample’ medications changed between admission and discharge. Which of the following statements is correct?
(a) Aspirin was discontinued.
(b) The patient started taking Pregabalin 50 mg, 1-0-0-0
(c) The dose of Sertraline hydrochloride was increased from 50 mg to 100 mg.
(d) The patient started taking prednisolone... | The patient started taking 2mg of Melatonin in the evening. | B | longhealth phase 1 | 0 | recompress |
null | patient_01_9 | longhealth_mcq | Based on the medication changes from admission to discharge, which of the following best describes the Mrs Sample's evolving clinical situation?
(a) The patient's cardiovascular risk was decreased, leading to a reduced number of cardiovascular medications at discharge.
(b) The patient's pain management was escalated, ... | The patient's pain management was escalated, as indicated by an increased frequency of Hydromorphone intake. | D. | longhealth phase 1 | 0 | recompress |
null | patient_01_10 | longhealth_mcq | It was decided that the Mrs. Sample’s current medication for multiple sclerosis should be changed. Which of the following statements is correct?
(a) On the 02/24/2017, an ambulatory physician recommended to indefinitely replace Fingolimod with Rituximab.
(b) During a consultation with an ambulatory physician, it was r... | During a consultation with an ambulatory physician, it was recommended to temporarily discontinue the current medication for multiple sclerosis, as the therapy for the patients DLBCL is also an effective treatment. | D. | longhealth phase 1 | 0 | recompress |
null | patient_01_11 | longhealth_mcq | Mrs. Sample underwent multiple imaging examinations. Which body part could not be assessed in these examinations?
(a) Liver
(b) Lungs
(c) Thyroid
(d) Uterus
(e) Feet | Feet | B | longhealth phase 1 | 0 | recompress |
null | patient_01_12 | longhealth_mcq | Which of these examinations were never performed in Mrs. Sample?
(a) Bone marrow aspiration
(b) CSF aspiration
(c) MRI of the head
(d) Pulmonary function testing
(e) Cardiac stress testing | Cardiac stress testing | B | longhealth phase 1 | 0 | recompress |
null | patient_01_13 | longhealth_mcq | According to the immunohistochemical findings in Mrs. Sample, which antibodies showed a positive reaction on the blastic tumor cells and what was the Ki-67 proliferation index for these cells?
(a) The blastic tumor cells showed a positive reaction after incubation with antibodies against CD20, CD30, and BCL2. The Ki-6... | The blastic tumor cells showed a positive reaction after incubation with antibodies against CD20, PAX5, and BCL2. The Ki-67 proliferation index for these blastic tumor cells is > 90%. | The blastic tumor cells showed a positive reaction after incubation with antibodies against CD20, PAX5, and BCL2. The Ki-67 proliferation index for these blastic tumor cells is > 90%.
The best answer is B. | longhealth phase 1 | 0 | recompress |
null | patient_01_14 | longhealth_mcq | Based on the microscopy findings for the epidural tumor in Mrs. Sample, what was the percentage of positivity for Bcl-6?
(a) <20%
(b) 0.2
(c) > 20%
(d) 0.3
(e) 0.35 | <20% | To answer this question, let's break down the process step by step:
1. The question asks for the percentage of positivity for Bcl-6 in the microscopy findings of the epidural tumor in Mrs. Sample.
2. Bcl-6 is a marker for certain types of cancer, including lymphoma.
3. The question mentions that the microscopy finding... | longhealth phase 1 | 0 | recompress |
null | patient_01_15 | longhealth_mcq | Regarding the molecular pathology report, which of the following statements is true for Mrs. Sample?
(a) The sample shows evidence of t(14;18) translocation.
(b) No clonal B-cell expansion was detected.
(c) No evidence of t(14;18) translocation
(d) The ligament sample showed evidence of tumor cells.
(e) The epidural ... | No evidence of t(14;18) translocation | C | longhealth phase 1 | 0 | recompress |
null | patient_01_16 | longhealth_mcq | Based on the Immunohistochemical processing results from 01/06/2017, which of the following is true for Mrs. Sample?
(a) Blastic tumor cells showed a negative reaction to MUM1.
(b) There was a positive reaction to both ALK1 and TdT.
(c) CD68-positive macrophages were absent in the sample.
(d) The epidural tumor was i... | The blastic tumor cells were positive for MUM1. | B. | longhealth phase 1 | 0 | recompress |
null | patient_01_17 | longhealth_mcq | Considering Mrs. Sample's medical records and the chronology of her radiological examinations, which of the following statements is true regarding the last imaging examination she underwent?
(a) A CT imaging of the spine was carried out, showing no material breakage.
(b) An MRI of her spine was performed, revealing a ... | A CT of the thorax was completed, showing an enlarged lymph node in station 10L. | D. | longhealth phase 1 | 0 | recompress |
null | patient_01_18 | longhealth_mcq | Regarding laboratory findings in Mrs. Sample, which parameter was elevated beyond the reference range in january 2017?
(a) Sodium
(b) Potassium
(c) Alkaline Phosphatase
(d) Creatinine
(e) Total Bilirubin | Alkaline Phosphatase | D | longhealth phase 1 | 0 | recompress |
null | patient_01_19 | longhealth_mcq | On clinical neurological assessment, Mrs. Sample demonstrated:
(a) Intense and persistent spasms in both legs
(b) Mild paraparesis in the right leg
(c) Severe neural abnormalities
(d) Mild paraparesis in the left leg
(e) Complete paralysis of the legs | Mild paraparesis in the left leg | A | longhealth phase 1 | 0 | recompress |
null | patient_02_0 | longhealth_mcq | What is the tumor proportion score (TPS) for PD-L1 status in Mrs. Done?
(a) 0.02
(b) <1%
(c) >1%
(d) TPS not available
(e) 0.03 | <1% | B | longhealth phase 1 | 0 | recompress |
null | patient_02_1 | longhealth_mcq | What would be the cumulative dose of Pembrolizumab in Mrs. Jane Done adjuvant chemotherapy?
(a) 1.6g
(b) 1.8g
(c) 2000mg
(d) 1.4g
(e) 1.6mg | 1.8g | To calculate the cumulative dose of Pembrolizumab, we need to know the dose administered per cycle and the number of cycles.
The question does not provide the dose per cycle, but it does provide the total dose.
Assuming the total dose is 2000mg, we can calculate the cumulative dose as follows:
Cumulative dose = Tota... | longhealth phase 1 | 0 | recompress |
null | patient_02_2 | longhealth_mcq | Where did Mrs. Done show metastases?
(a) brain, lungs, liver, heart, lymph nodes, muscles, bones
(b) cerebellum, liver, pancreas, lungs, bones
(c) bones, skin, adrenals, lungs, brain, bladder
(d) lunga, liver, lymphnodes, muscles, bones
(e) brain, lymph nodes, lungs, liver, muscles, bones | brain, lungs, liver, heart, lymph nodes, muscles, bones | B | longhealth phase 1 | 0 | recompress |
null | patient_02_3 | longhealth_mcq | When did Mrs. Done start Radiotherapy?
(a) March 2020
(b) January 2020
(c) May 2020
(d) Februrary 2020
(e) June 2020 | Februrary 2020 | C | longhealth phase 1 | 0 | recompress |
null | patient_02_4 | longhealth_mcq | Upon the discharge of Mrs. Done, which of the lab values were outside the reference ranges?
(a) all values were in reference range
(b) low TSH
(c) low Platelets
(d) low Hemoglobin(11.5 g/dL, normal range 12-16 g/dL)
(e) Gamma-GT (GGT): 75 U/l | all values were in reference range | D | longhealth phase 1 | 0 | recompress |
null | patient_02_5 | longhealth_mcq | What was the total duration of Mrs. Jane Done's hospital stay during her most recent admission?
(a) 11 days (02/18/2018 to 03/01/2018)
(b) 1 month (02-03-/20)
(c) 15 days (02/14/2022 to 03/01/2022)
(d) 24 days (05/ß2/20 - 05/26/20)
(e) 14 days (03/16/2021 - 03/30/2021) | 15 days (02/14/2022 to 03/01/2022) | A | longhealth phase 1 | 0 | recompress |
null | patient_02_6 | longhealth_mcq | Based on Mrs. Jane Done's hospital course, which of the following statements is accurate?
(a) The patient underwent a microsurgical resection for a left frontal hemorrhaged metastasis from previously diagnosed malignant melanoma on 01/20.
(b) During one of her hospital stays, Mrs. Done was treated for a cystic metasta... | The patient has undergone empyema removal due to an infection following her resection of a right frontal tumor, which took place in February 2020 | B. | longhealth phase 1 | 0 | recompress |
null | patient_02_7 | longhealth_mcq | According to the most recent PET-CT findings in Mrs. Done, what is the Standard Uptake Value (SUVmax) of the lesion abutting the lateral wall of the left ventricle?
(a) 7.4
(b) 8.8
(c) 9.5
(d) 8.2
(e) 7.1 | 9.5 | A. | longhealth phase 1 | 0 | recompress |
null | patient_02_8 | longhealth_mcq | What mutation was found in Mrs. Done's molecular profile, which is specifically targeted by the recommended therapeutic combination?
(a) ALK-EML4
(b) RAS
(c) BRAF V600E
(d) EGFR
(e) KRAS | BRAF V600E | C | longhealth phase 1 | 0 | recompress |
null | patient_02_9 | longhealth_mcq | Regarding Mrs. Done, hat is the parameter mentioned that warrants immediate medical attention according to the treatment regimen?
(a) Blood pressure exceeding 160/90 mmHg
(b) Body temperature surpassing 38.3°C
(c) Any elevated liver enzymes
(d) Blood glucose levels above 200 mg/dL
(e) Drop in white blood cell count be... | Body temperature surpassing 38.3°C | C | longhealth phase 1 | 0 | recompress |
null | patient_02_10 | longhealth_mcq | According to the macroscopy report section in Mrs. Done, what was the closest approach of the resection margins to the tumor?
(a) Less than 0.05 cm
(b) Less than 0.15 cm
(c) Less than 0.25 cm
(d) Less than 0.30 cm
(e) This information was not provided | Less than 0.15 cm | C | longhealth phase 1 | 0 | recompress |
null | patient_02_11 | longhealth_mcq | Based on the discharge letter, which of the following statements best represents Mrs. Jane Done's SARS-CoV-2 status and its trend during her hospitalization?
(a) Her viral load increased while Ct values decreased from admission to discharge.
(b) Both her viral load and Ct values remained unchanged during her hospital ... | Her viral load decreased, but Ct values remained the same from admission to discharge. | D. | longhealth phase 1 | 0 | recompress |
null | patient_02_12 | longhealth_mcq | What surgical steps were taken in Mrs. Done during the neck dissection procedure performed on 01/05/2021?
(a) The auricularis magnus nerve could be preserved.
(b) The accessory nerve was identified and severed.
(c) The auricularis magnus nerve was severed, the accessory nerve was preserved.
(d) The accessory nerve co... | The auricularis magnus nerve was severed, the accessory nerve was preserved. | C | longhealth phase 1 | 0 | recompress |
null | patient_02_13 | longhealth_mcq | What was the initial procedure performed for Mrs. Jane Done in February 2018?
(a) Excision of benign nevus on the right shoulder
(b) Excision of malignant melanoma on the left upper back
(c) Biopsy of a mole on the left arm
(d) Microsurgical resection of right frontal tumor
(e) Excision of empyema | Excision of malignant melanoma on the left upper back | C | longhealth phase 1 | 0 | recompress |
null | patient_02_14 | longhealth_mcq | Which of the following medications was given to the Mrs. Done for eczema treatment during the hospital stay from 10/23/2020 to 11/01/2020?
(a) Paracetamol
(b) Pembrolizumab
(c) Desonide Cream
(d) Levothyroxine
(e) Calcium Supplement | Desonide Cream | B | longhealth phase 1 | 0 | recompress |
null | patient_02_15 | longhealth_mcq | Regarding Mrs. Done, what histopathological diagnosis was provided for the excised melanoma on 02/23/2018?
(a) Benign melanocytic nevus
(b) Atypical melanocytic proliferation
(c) Exophytic, ulcerated malignant melanoma with a tumor thickness of 5 mm
(d) Exophytic, ulcerated malignant melanoma with a tumor thickness of... | Exophytic, ulcerated malignant melanoma with a tumor thickness of at least 15 mm | C. | longhealth phase 1 | 0 | recompress |
null | patient_02_16 | longhealth_mcq | Following Mrs. Done's microsurgical resection on 01/02/2020, what did the MRI brain report dated 01/04/2020 primarily indicate about the surgical site?
(a) Evidence of residual tumor in the surgical bed
(b) Hydrocephalus and midline shift
(c) Evidence of new metastatic foci
(d) Post-surgical changes with no evidence o... | Post-surgical changes with no evidence of residual tumor | D | longhealth phase 1 | 0 | recompress |
null | patient_02_17 | longhealth_mcq | During the Mrs. Done's stay from 10/23/2020 to 11/01/2020, which incident occurred on 10/28/2020?
(a) The patient developed a drug exanthema.
(b) The patient started Nivolumab and Ipilimumab therapy.
(c) The patient had an unattended fall leading to a hematoma on the left forehead.
(d) The patient was diagnosed with h... | The patient had an unattended fall leading to a hematoma on the left forehead. | C | longhealth phase 1 | 0 | recompress |
null | patient_02_18 | longhealth_mcq | According toMrs. Done's PET/CT findings, which cervical lymph node level did NOT show increased FDG uptake consistent with metastatic disease?
(a) Left Level II
(b) Right Level II
(c) Left Level IV
(d) Right Level IV
(e) Retropharyngeal space | Right Level IV | C | longhealth phase 1 | 0 | recompress |
null | patient_02_19 | longhealth_mcq | Which of the following best describes Mrs. Done's lab results for Hemoglobin upon discharge?
(a) 12.3 g/dL
(b) 12.4 g/dL
(c) Below normal range
(d) Above normal range
(e) 11.5 g/dL | 12.4 g/dL | C | longhealth phase 1 | 0 | recompress |
null | patient_03_0 | longhealth_mcq | Where was osteolysis detected in Mr. John Williams in October 2015?
(a) First cervical vertebra
(b) Seventh thoracic vertebra
(c) First lumbar vertebra
(d) B and C
(e) Fourth thoracic vertebra | B and C | C | longhealth phase 1 | 0 | recompress |
null | patient_03_1 | longhealth_mcq | Which treatment resulted in prolonged pancytopenia for Mr. Williams?
(a) Cyclophosphamide, bortezomib and dexamethasone
(b) Combination of carfilzomib, lenalidomide, and dexamethasone
(c) Stem cell mobilization using cyclophosphamide
(d) Cyclophosphamide–carfilzomib–dexamethasone
(e) None of the above | Cyclophosphamide, bortezomib and dexamethasone | B. | longhealth phase 1 | 0 | recompress |
null | patient_03_2 | longhealth_mcq | Based on the immunohistochemical additional findings in Mr. Williams, what percentage of blast cells were positive for CD34 and CD117?
(a) Above 10%
(b) Above 5%
(c) Below 5%
(d) Exactly 5%
(e) Below 1% | Below 5% | Based on the immunohistochemical additional findings in Mr. Williams, the percentage of blast cells positive for CD34 and CD117 is:
A. Above 10%
The correct answer is A. | longhealth phase 1 | 0 | recompress |
null | patient_03_3 | longhealth_mcq | From the PSMA-PET-CT scan results for Mr. Williams, which vertebra showed the most notable PSMA uptake?
(a) C4
(b) L1
(c) Th4
(d) Th7
(e) L5 | Th4 | C | longhealth phase 1 | 0 | recompress |
null | patient_03_4 | longhealth_mcq | On 01/09/2017, Mr. Williams received a CT scan of her whole body. What kind of contrast agent was used?
(a) Omnipaque 320
(b) Imeron 400
(c) Optiray 320
(d) Omnipaque 240
(e) Ultravist 370 | Omnipaque 240 | C | longhealth phase 1 | 0 | recompress |
null | patient_03_5 | longhealth_mcq | Mr. Williams received multiple radiologic examinations. In which order did she receive them?
(a) CT Whole Body > MR Spine Scan > CT Spine Scan > PSMA-PET-CT Scan > CT Chest > CT Whole Body > Whole Body CT scan
(b) Whole Body CT scan > CT Spine Scan > CT Whole Body > MR Spine Scan > CT Chest > PSMA-PET-CT Scan > CT Who... | CT Whole Body > CT Whole Body > CT Chest > CT Chest > PSMA-PET-CT Scan > MR Spine Scan > CT Spine Scan > Whole Body CT scan > Chest X-ray | A. | longhealth phase 1 | 0 | recompress |
null | patient_03_6 | longhealth_mcq | Mr. Williams’ medications changed between 2018 and March 2019 - how did they change when looking at March 2019?
(a) Lenalidomide 5 mg nightly and Bisoprolol 2.5 mg were discontinued.
(b) The patient started taking Lyrica 25 mg and Lenalidomide 5 mg nightly.
(c) The patient started taking Zofran 8 mg as needed.
(d) The... | Amlodipin 5 mg was paused. | B | longhealth phase 1 | 0 | recompress |
null | patient_03_7 | longhealth_mcq | Based on Mr. Williams' medication changes between the first and last recorded medication, which of the following best describes the changes?
(a) Pantoprazole's dosage increased from once daily to twice daily, and Valtrex was discontinued at discharge.
(b) Cyclosporine and Myfortic were both continued at discharge, whi... | Duragesic was added with a dosing instruction to change every 3 days. | D. | longhealth phase 1 | 0 | recompress |
null | patient_03_8 | longhealth_mcq | Which sequence of events, as presented in Mr. Williams's detailed medical report, is accurate?
(a) Mitral valve reconstruction via minithoracotomy in 2015, multiple myeloma diagnosis in 2015, prostate carcinoma diagnosis in January 2018, followed by brainstem transient ischemic attack (TIA) in March 2020.
(b) Multiple... | First diagnosis of multiple myeloma in 2015, mitral valve reconstruction in 2015, prostate carcinoma diagnosis in January 2018, and then acute mitral valve endocarditis in March 2020. | D. | longhealth phase 1 | 0 | recompress |
null | patient_03_9 | longhealth_mcq | Considering Mr. John Williams's treatment journey for his Multiple Myeloma condition, which of the following sequences regarding his treatment chronology is correct?
(a) Started with Bortezomib and Dexamethasone in 2018, switched to Carfilzomib, Lenalidomide, and Dexamethasone, received radiation to Th4 and the thorac... | Received radiation to Th4 and the thoracic rib in August 2018, underwent three cycles of Pomalidomide, Doxorubicin, and Dexamethasone between August and October 2018, and then received four treatments of Daratumumab, Lenalidomide, and Dexamethasone from November 2018 to February 2019. | B. | longhealth phase 1 | 0 | recompress |
null | patient_03_10 | longhealth_mcq | Which of these examinations were never performed in Mr. Williams?
(a) Whole spine MRI
(b) Ophthalmological exams
(c) Bone marrow aspiration
(d) Echocardiography
(e) Cardiac stress test | Cardiac stress test | C | longhealth phase 1 | 0 | recompress |
null | patient_03_11 | longhealth_mcq | Based on the clinical history of Mr. John Williams, which of the following statements is accurate?
(a) Mr. Williams underwent a mitral valve replacement in March 2019 due to Acute mitral valve endocarditis, with all infected tissue resected from the mitral valve's holding apparatus. The cause of the infection was asso... | Mr. Williams presented with symptoms of fatigue, shortness of breath, and bilateral pitting edema in the lower extremities in November 2022. Preliminary findings included a reduced LVEF of 35%, elevated BNP levels, and an echocardiogram showing mild mitral regurgitation. | D | longhealth phase 1 | 0 | recompress |
null | patient_03_12 | longhealth_mcq | Which of the following treatments did Mr. John Williams receive in August 2018?
(a) Daratumumab, lenalidomide, and dexamethasone.
(b) Radiation therapy to Th4 of the rib thorax.
(c) VelDex due to impaired renal function.
(d) Mobilization chemotherapy with cyclophosphamide.
(e) Androgen blockade using Enantone for pros... | Radiation therapy to Th4 of the rib thorax. | D. | longhealth phase 1 | 0 | recompress |
null | patient_03_13 | longhealth_mcq | What was the tumor board's decision regarding Mr. John Williams' future therapy on March 3, 2019?
(a) Continue with daratumumab, Revlimid, and dexamethasone and undergo stem cell mobilization with autologous stem cell transplant.
(b) Begin treatment with Enantone for prostate carcinoma.
(c) Initiate radiation therapy ... | Continue with daratumumab, Revlimid, and dexamethasone and undergo stem cell mobilization with autologous stem cell transplant. | A. | longhealth phase 1 | 0 | recompress |
null | patient_03_14 | longhealth_mcq | What imaging method and findings provided evidence of Mr. Williams's metastatic involvement at the level of T4 vertebral body consistent with prostate cancer?
(a) A CT Spine scan on 09/30/2018 which showed extensive osteolysis in multiple vertebral bodies.
(b) An MRI of the entire spine on 06/20/2018 which revealed di... | A PSMA-PET-CT Scan in 05/2018 which exhibited notably increased PSMA uptake at the level of T4 vertebral body, showing evidence of metastatic involvement. | C. | longhealth phase 1 | 0 | recompress |
null | patient_03_15 | longhealth_mcq | Based on the provided information, which of the following treatment combinations was Mr. Williams on, specifically targeting his diagnosis of Multiple Myeloma?
(a) Velcade, Dexamethasone, and Enantone.
(b) Velcade, Daratumumab, and Bondronate.
(c) Velcade, Dexamethasone, and Lenalidomide.
(d) Velcade, Cotrim forte, an... | Velcade, Dexamethasone, and Lenalidomide. | C. | longhealth phase 1 | 0 | recompress |
null | patient_03_16 | longhealth_mcq | What was NOT observed in Mr. Williams' bone marrow biopsy microscopic examination?
(a) Increased erythropoiesis
(b) Enhanced hemosiderosis
(c) Evidence of bone marrow edema
(d) Atypical proliferation of plasma cells
(e) Normocellular medullary canals | Atypical proliferation of plasma cells | D | longhealth phase 1 | 0 | recompress |
null | patient_03_17 | longhealth_mcq | Which treatment was administered to Mr. Williams in the period 03/15 - 06/15?
(a) Cyclophosphamide–bortezomib–dexamethasone
(b) Carfilzomib/Lenolidomide/Dexamethasone
(c) Stem cell mobilization with cyclophosphamide
(d) Darzalex 16mg/kg
(e) Cyclosporine 200mg daily | Carfilzomib/Lenolidomide/Dexamethasone | B | longhealth phase 1 | 0 | recompress |
null | patient_03_18 | longhealth_mcq | According to the FISH results from the histological findings in 03/2015, which of the following was detected in Mr. Williams?
(a) Only one trisomy or tetrasomy 9
(b) Presence of five trisomy or tetrasomy 9
(c) No additional signals for CCND1
(d) No additional signals for 5p15- and 5q31-
(e) 45, XY with a detected ASxL... | Only one trisomy or tetrasomy 9 | C. | longhealth phase 1 | 0 | recompress |
null | patient_03_19 | longhealth_mcq | What complication did Mr. Williams NOT experience after receiving medical treatment?
(a) Mucositis
(b) Gastrointestinal symptoms
(c) E. faecium infection
(d) JC virus bladder infection
(e) Pulmonary embolism | Pulmonary embolism | D | longhealth phase 1 | 0 | recompress |
null | patient_04_0 | longhealth_mcq | When did Mrs. Jill Anderson first notice scleral and cutaneous icterus?
(a) July 2021
(b) August 2021
(c) September 2021
(d) October 2021
(e) November 2021 | August 2021 | C | longhealth phase 1 | 0 | recompress |
null | patient_04_1 | longhealth_mcq | Which of the following diagnoses was Mrs. Anderson NOT associated with during her visits in the described records?
(a) Luxation of the shoulder joint
(b) Fracture tuberculum majus humeri
(c) Ankle sprain on the right side
(d) Mild skin itching
(e) Fracture of the right wrist | Fracture of the right wrist | D. | longhealth phase 1 | 0 | recompress |
null | patient_04_2 | longhealth_mcq | Regarding her pancreatic condition, which procedure was Mrs. Anderson subjected to on 09/29/21?
(a) Surgical port placement
(b) Endoscopic ultrasound-guided FNA
(c) Radiation therapy
(d) Neoadjuvant chemotherapy with FOLFIRINOX
(e) Thyroidectomy | Endoscopic ultrasound-guided FNA | D | longhealth phase 1 | 0 | recompress |
null | patient_04_3 | longhealth_mcq | Based on the findings from the CT scan of the chest and abdomen performed on 09/28/21, which of the following statements is TRUE for Mrs. Anderson?
(a) There was evidence of distant metastases.
(b) The mass in the pancreatic head was in contact with the SMA (>180°).
(c) Suspicious regional lymph nodes were particularl... | The liver showed signs of fatty infiltration. | D. | longhealth phase 1 | 0 | recompress |
null | patient_04_4 | longhealth_mcq | What recommendation was made by the Gastrointestinal Tumor Board on September 30th, 2021 regarding Mrs. Anderson's treatment?
(a) Immediate surgery to remove the tumor.
(b) Start radiation therapy immediately.
(c) Begin neoadjuvant chemotherapy with FOLFIRINOX and review after 4 cycles.
(d) Wait for final histology an... | Begin neoadjuvant chemotherapy with FOLFIRINOX and review after 4 cycles. | D. | longhealth phase 1 | 0 | recompress |
null | patient_04_5 | longhealth_mcq | What was the histopathological finding related to the gallbladder during the exploratory laparotomy performed in Mrs. Anderson?
(a) Acute cholecystitis.
(b) Cholelithiasis.
(c) Chronic cholecystitis.
(d) Gallbladder polyps.
(e) Gallbladder adenocarcinoma. | Chronic cholecystitis. | C. | longhealth phase 1 | 0 | recompress |
null | patient_04_6 | longhealth_mcq | In Mrs. Anderson's CT scan from September 28, 2021, what was noted about the mass in the head of the pancreas?
(a) A hypodense mass measuring 34 x 28 mm.
(b) It had direct contact with the liver.
(c) It was >180° around the superior mesenteric artery.
(d) No dilation of the pancreatic duct was observed.
(e) None of th... | A hypodense mass measuring 34 x 28 mm. | D | longhealth phase 1 | 0 | recompress |
null | patient_04_7 | longhealth_mcq | Which sequence correctly lists radiologic examinations Mrs. Anderson underwent in chronological order?
(a) Shoulder X-ray > Right ankle X-ray > Foot X-ray > Chest X-ray > Chest/abdomen/pelvis CT > CT staging > Abdominal MRI > CT staging > Ultrasound
(b) Right ankle X-ray > Foot X-ray > Shoulder X-ray > Chest/abdomen/p... | Foot X-ray > Shoulder X-ray > Right ankle X-ray > Chest/abdomen/pelvis CT > Ultrasound > Abdominal MRI > CT stagings > Chest X-rays > CT Chest/Abdomen/Pelvis with contrast | A. | longhealth phase 1 | 0 | recompress |
null | patient_04_8 | longhealth_mcq | According to the GI Tumor Board Review on January 9th, 2022, which of the following statements is true for Mrs. Anderson?
(a) The CT scan showed signs of liver metastases.
(b) The CT scan indicated remission of her tumor.
(c) The CT scan showed progression of her tumor.
(d) Distant metastases were identified.
(e) The ... | The CT scan showed progression of her tumor. | D | longhealth phase 1 | 0 | recompress |
null | patient_04_9 | longhealth_mcq | Mrs. Anderson's tumor marker Ca19-9 levels in September 2021 were:
(a) 525 U/ml.
(b) 575 U/ml.
(c) 380 U/ml.
(d) 425 U/ml.
(e) 680 U/ml. | 575 U/ml. | C | longhealth phase 1 | 0 | recompress |
null | patient_04_10 | longhealth_mcq | Which of the following statements regarding Mrs. Anderson's chemotherapy is accurate?
(a) She underwent FOLFIRINOX as neoadjuvant chemotherapy for 5 cycles.
(b) Gemcitabine/nab-paclitaxel was started in 07/22 after surgery.
(c) She underwent 4 cycles of gemcitabine/nab-paclitaxel from 02/22 to 06/22.
(d) FOLFIRINOX wa... | Gemcitabine/nab-paclitaxel was started in 07/22 after surgery. | C | longhealth phase 1 | 0 | recompress |
null | patient_04_11 | longhealth_mcq | What change in the lung nodules was observed in the CT scan dated 04/02/2023 as compared to the prior scan in Mrs. Anderson?
(a) Lung nodules were significantly reduced in size.
(b) Lung nodules remained unchanged in size and number.
(c) Known metastatic lung nodules increased in size.
(d) No known metastatic lung nod... | Known metastatic lung nodules increased in size. | A | longhealth phase 1 | 0 | recompress |
null | patient_04_12 | longhealth_mcq | Discuss the rationale behind the shift from neoadjuvant FOLFIRINOX therapy to gemcitabine/nab-paclitaxel in Mrs. Anderson.
(a) FOLFIRINOX was not available.
(b) Patient showed allergic reactions to FOLFIRINOX.
(c) FOLFIRINOX was given as palliative therapy.
(d) Disease progression despite neoadjuvant FOLFIRINOX therap... | Disease progression despite neoadjuvant FOLFIRINOX therapy. | E. | longhealth phase 1 | 0 | recompress |
null | patient_04_13 | longhealth_mcq | Regarding Mrs. Anderson, which is NOT a finding from the CT scan dated 12/02/2022?
(a) Pancreatic tumor decreasing in size
(b) Suspicious pulmonary nodules
(c) Fatty liver
(d) Elongation of the right iliac artery
(e) No new liver lesions | Suspicious pulmonary nodules | D | longhealth phase 1 | 0 | recompress |
null | patient_04_14 | longhealth_mcq | What was the diagnosis for Mrs. Anderson during her inpatient treatment from 07/20/2023 to 09/12/2023?
(a) Seropneumothorax due to a clot at the port tip
(b) Seropneumothorax due to lung metastasis from pancreatic carcinoma
(c) Seropneumothorax secondary to punction of a malignant pleural effusion with progressive pul... | Seropneumothorax secondary to punction of a malignant pleural effusion with progressive pulmonary metastasis of a pancreatic head carcinoma | C. | longhealth phase 1 | 0 | recompress |
null | patient_04_15 | longhealth_mcq | Which medication was prescribed to Mrs. Anderson for her mental health concerns?
(a) Diazepam
(b) Paracetamol
(c) Mirtazapine
(d) Novalgin
(e) Cisplatin | Mirtazapine | C | longhealth phase 1 | 0 | recompress |
null | patient_04_16 | longhealth_mcq | As of her discharge in September 2023, how was Mrs. Anderson's pleural effusion status?
(a) Slightly increased at around 200-300ml/day but clinically stable
(b) Slightly increased at around 100-200ml/day but clinically stable
(c) Drastically improved with no evidence of fluid
(d) Required another round of drainage bef... | Slightly increased at around 100-200ml/day but clinically stable | C | longhealth phase 1 | 0 | recompress |
null | patient_04_17 | longhealth_mcq | Based on the pathology report from 07/26/2023, which of the following findings was NOT present in Mrs. Anderson's liquid sample?
(a) Red blood cells
(b) Atypical cells in clusters
(c) Evidence of a fungal infection
(d) Many granulocytes
(e) Active mesothelium | Evidence of a fungal infection | B | longhealth phase 1 | 0 | recompress |
null | patient_04_18 | longhealth_mcq | Based on the sequence of interventions and radiologic findings, which of the following statements is accurate regarding Mrs. Anderson's clinical progression?
(a) The pathology report confirmed the presence of fungal cells in the pleural fluid prior to the placement of the chest tube on 07/24/2023.
(b) Following the ch... | The pleural effusion that was initially drained led to an improvement in oxygen saturation, but was followed by the development of a seropneumothorax, necessitating a chest tube placement. | D. | longhealth phase 1 | 0 | recompress |
null | patient_04_19 | longhealth_mcq | Which of the following medications was present during Mrs. Anderson's initial therapy but not at the time of the last discharge?
(a) Lovenox
(b) Paracetamol
(c) Mirtazapine
(d) Novalgin
(e) Pancreatic enzymes | Lovenox | A | longhealth phase 1 | 0 | recompress |
null | patient_05_0 | longhealth_mcq | What was the initial presentation that led Mr. John Miller to be admitted?
(a) Migraine
(b) Loss of conciousness
(c) Speech disturbances
(d) Tremors
(e) Seizures | Speech disturbances | C | longhealth phase 2 | 1 | recompress |
null | patient_05_1 | longhealth_mcq | When was the recurrence of Mr. Miller's glioblastoma resected?
(a) 08/15/19
(b) 08/01/19
(c) 08/11/19
(d) 10/12/19
(e) 12/01/19 | 10/12/19 | C | longhealth phase 2 | 1 | recompress |
null | patient_05_2 | longhealth_mcq | What molecular pathology finding is observed in Mr. Miller's condition?
(a) Combined 1p/19q loss
(b) p.R132H mutation in IDH
(c) CDKN2A/B deletion
(d) KRAS mutation
(e) BRAF V600E mutation | CDKN2A/B deletion | B | longhealth phase 2 | 1 | recompress |
null | patient_05_3 | longhealth_mcq | Regarding Mr. Miller, based on the findings from the CT scan of the chest and abdomen performed on 09/28/21, which of the following statements is TRUE?
(a) 5 hours 10 minutes
(b) 6 hours 10 minutes
(c) 4 hours 10 minutes
(d) 3 hours 50 minutes
(e) 4 hours 30 minutes | 4 hours 10 minutes | C | longhealth phase 2 | 1 | recompress |
null | patient_05_4 | longhealth_mcq | How much does Mr. Miller's Karnofsky Performance Score change over the course of therapy?
(a) Decreases by 20%.
(b) Decreases by 10%.
(c) Decreases by 30%.
(d) Increases by 10%.
(e) No change. | Decreases by 10%. | B. | longhealth phase 2 | 1 | recompress |
null | patient_05_5 | longhealth_mcq | Regarding Mrs. Miller, what recommendation was given by the Interdisciplinary Neuro-oncological Tumor Board on 04/20/2020?
(a) Initiation of radiotherapy
(b) Further surgeries
(c) Observation without treatment
(d) Reinitiation of Temozolomide chemotherapy
(e) Change in medication regimen | Reinitiation of Temozolomide chemotherapy | D | longhealth phase 2 | 1 | recompress |
null | patient_05_6 | longhealth_mcq | Which of the following medications was increased in dosage during Mr. Miller's therapy?
(a) Allopurinol
(b) Bisoprolol
(c) Levetiracetam
(d) Januvia
(e) Lisinopril | Levetiracetam | D. | longhealth phase 2 | 1 | recompress |
null | patient_05_7 | longhealth_mcq | Which method was employed for Mr. Miller's radiotherapy?
(a) Intensity-modulated radiotherapy
(b) Stereotactic radiosurgery
(c) GammaKnife
(d) Helical tomotherapy
(e) Both a) and d) | Both a) and d) | C | longhealth phase 2 | 1 | recompress |
null | patient_05_8 | longhealth_mcq | According to Mr. Miller's MRI report dated 02/02/2021, which of the following is observed?
(a) There is no midline shift.
(b) The width of both the internal and external CSF spaces decreased.
(c) The orbital contents are asymmetrical.
(d) Residual blood products are noted within the resection cavity.
(e) The paranasal... | Residual blood products are noted within the resection cavity. | D. | longhealth phase 2 | 1 | recompress |
null | patient_05_9 | longhealth_mcq | Which of the following statements accurately reflects the changes in Mr. John Miller's medication regimen from earlier prescriptions to his last recorded discharge?
(a) Levetiracetam, previously prescribed at 1000mg once daily in the morning, was maintained at the same dosage upon discharge.
(b) Lisinopril, initially ... | Januvia, initially given at 50 mg twice daily, was discontinued and levothyroxine sodium 50 μg was added. | B. | longhealth phase 2 | 1 | recompress |
null | patient_05_10 | longhealth_mcq | How many times was glioblastoma resection performed on Mr. John Miller by the reporting facility prior to 2021?
(a) Once
(b) Twice
(c) Thrice
(d) Four times
(e) Never | Thrice | B | longhealth phase 2 | 1 | recompress |
null | patient_05_11 | longhealth_mcq | Which area showed a notable reduction in the barrier disturbance in Mr. Miller's cMRI scan from 06/02/2021?
(a) Right parietal lobe
(b) Left basal ganglia
(c) Right-sided basal ganglia
(d) Left frontal lobe
(e) Right cerebellum | Right-sided basal ganglia | C. | longhealth phase 2 | 1 | recompress |
null | patient_05_12 | longhealth_mcq | Which imaging modality was scheduled for Mr. John Miller on 06/02/2021?
(a) PET scan
(b) Ultrasound
(c) MRI
(d) CT scan
(e) X-ray | MRI | D | longhealth phase 2 | 1 | recompress |
null | patient_05_13 | longhealth_mcq | Which of the following medications was NOT mentioned in Mr. Miller's report on admission in 2019?
(a) Lacosamide 100 mg/1 pc
(b) Lorazepam 0.5 mg/1 pc
(c) Levothyroxine sodium 50 μg/1 pc
(d) Acetaminophen 500 mg
(e) Sertraline 50 mg | Acetaminophen 500 mg | D | longhealth phase 2 | 1 | recompress |
null | patient_05_14 | longhealth_mcq | Which molecular pathological finding was technically not evaluable (immunohistochemical) for Mr. Miller?
(a) ATRX
(b) IDH status
(c) p53
(d) CDKN2A/B
(e) MGMT promoter | p53 | D | longhealth phase 2 | 1 | recompress |
null | patient_05_15 | longhealth_mcq | During which month and year did Mr. Miller first experience symptoms such as speech disturbances and confusion?
(a) 2018-07-01 00:00:00
(b) 2019-08-01 00:00:00
(c) 2019-07-01 00:00:00
(d) 2019-06-01 00:00:00
(e) 2018-12-01 00:00:00 | 2019-07-01 00:00:00 | D. 2019-06-01 00:00:00 | longhealth phase 2 | 1 | recompress |
null | patient_05_16 | longhealth_mcq | What was the height of Mr. Miller as indicated in one of the reports?
(a) 169 cm
(b) 160 cm
(c) 180 cm
(d) 175 cm
(e) 170 cm | 175 cm | B. 160 cm | longhealth phase 2 | 1 | recompress |
null | patient_05_17 | longhealth_mcq | Regarding Mr. Miller, based on the pathology report from 07/26/2023, which of the following findings was NOT present in the liquid sample?
(a) IDH mutation (R132H)
(b) ATRX: preservation of nuclear expression
(c) p53: technically not evaluable
(d) MGMT promoter: Non-methylated
(e) CDKN2A/B: Deleted | MGMT promoter: Non-methylated | D | longhealth phase 2 | 1 | recompress |
null | patient_05_18 | longhealth_mcq | Which of these developments in Mr. Miller's treatment occurred on 02/2021?
(a) Repeat stereotactic RTx
(b) New FLAIR-positive tumor manifestation insular on the right side
(c) Glioblastoma resection
(d) Start of radiochemotherapy
(e) Wound revision and flap plasty | New FLAIR-positive tumor manifestation insular on the right side | C | longhealth phase 2 | 1 | recompress |
write-rule least: five-phase monolithic update, budgets 1024 and 16384
Results of scripts/farid_handoff/write-rule-least/write_rule_least.sh from
faridlazuarda/gated-continual-cartridges, branch moe-am (commit 05ee8ff6), run on
2026-11-14 with one NVIDIA H100 80GB per run through Slurm. The monolithic update with
--write-rule least: each phase may change only the budget/4 memory slots the re-fit
queries attend to least, so the most-attended memory is kept as it is.
Included: all eight runs: set1-4 (budget 1024) and set5-8 (budget 16384).
Differences from the handoff script
--vllm-mem 0.35instead of the config's 0.18. On an 80 GB card, 0.18 leaves vLLM 0.88 GiB of KV cache against the 9.00 GiB that--vllm-max-len 65536needs, so vLLM does not start. 0.35 gives 14.34 GiB, about what 0.18 gives on a ~180 GB B200. This only changes how much memory vLLM reserves; the method is unchanged.COMPACTION_CACHE=0andOMP/MKL_NUM_THREADS=8, as inscripts/launch/dgx/w30.- Python 3.12 venv with torch 2.8.0+cu128, transformers 4.57.1, vllm 0.11.0 (the
README's versions;
requirements.txt/pyproject.tomlpin torch 2.14.1 / transformers 5.19.0 instead). venv instead of conda, Hugging Face offline mode.
The 16384-slot runs fit on an 80 GB H100: the highest card use seen was ~60 GB (set7's merge); the others peaked lower.
Accuracy (the paper's Acc / Fgt / Unp, percent)
From scripts/score/run_metrics.py <run_dir>; the per-file scores are the
r.generations_phase<k>.scores.json next to each answer file.
| Set | Budget | Run | Acc | Fgt | Unp | per phase after phase 5 (1/2/3/4/5) |
|---|---|---|---|---|---|---|
| set1 | 1024 | longhealth_qwen | 27.7 | 3.8 | 2.0 | 31.2 / 23.8 / 30.0 / 27.5 / 26.2 |
| set2 | 1024 | longhealth_llama | 17.8 | 17.5 | 0.2 | 20.0 / 12.5 / 13.8 / 21.2 / 21.2 |
| set3 | 1024 | quality_qwen | 39.1 | 0.8 | 1.9 | 42.7 / 35.9 / 36.9 / 44.4 / 35.2 |
| set4 | 1024 | quality_llama | 0.0 | 23.8 | 99.8 | 0.0 / 0.0 / 0.0 / 0.0 / 0.0 |
| set5 | 16384 | longhealth_qwen | 32.5 | 23.1 | 8.8 | 33.8 / 17.5 / 22.5 / 46.2 / 42.5 |
| set6 | 16384 | longhealth_llama | 36.0 | 7.2 | 0.0 | 30.0 / 47.5 / 32.5 / 30.0 / 40.0 |
| set7 | 16384 | quality_qwen | 39.7 | 11.4 | 1.1 | 37.1 / 37.5 / 42.6 / 47.6 / 33.6 |
| set8 | 16384 | quality_llama | 31.1 | 9.0 | 0.3 | 29.0 / 35.2 / 30.3 / 36.5 / 24.6 |
set4 (1024, QuALITY, Llama) collapses: overall accuracy after phases 1-5 is 36.3 / 34.1 / 25.4 / 5.8 / 0.0. After phase 4 most replies are "I'll do my best to help you."; after phase 5 almost all are "I can't help you." or "I can help you." with no option letter. The same pair at 16384 (set8) does not degenerate (Unp 0.3).
Log-perplexity of the reference answers (lower is better)
forget = final minus right-after-learning, per phase 1-4 (negative = improved).
| Set | Budget / write-slots | Run | avg_final | avg_forget | forget per phase | runtime |
|---|---|---|---|---|---|---|
| set1 | 1024 / 256 | longhealth_qwen | 1.7930 | -0.1410 | -0.132 / -0.228 / -0.178 / -0.026 | 03:02:57 |
| set2 | 1024 / 256 | longhealth_llama | 1.2192 | -0.0591 | -0.167 / -0.004 / +0.037 / -0.103 | 00:46:16 |
| set3 | 1024 / 256 | quality_qwen | 1.9407 | +0.0998 | -0.032 / +0.178 / +0.036 / +0.217 | 03:45:15 |
| set4 | 1024 / 256 | quality_llama | 1.4124 | +0.1389 | +0.090 / +0.098 / +0.358 / +0.011 | 01:12:12 |
| set5 | 16384 / 4096 | longhealth_qwen | 1.7957 | -0.1222 | -0.109 / -0.167 / -0.103 / -0.109 | 04:35:30 |
| set6 | 16384 / 4096 | longhealth_llama | 1.1175 | -0.1916 | -0.241 / -0.347 / -0.136 / -0.042 | 01:51:30 |
| set7 | 16384 / 4096 | quality_qwen | 1.6897 | -0.0881 | -0.147 / -0.141 / -0.017 / -0.047 | 06:34:43 |
| set8 | 16384 / 4096 | quality_llama | 1.0819 | -0.3298 | -0.315 / -0.513 / -0.443 / -0.048 | 01:40:56 |
Layout
monolithic_update_{1k,16k}_wincap_least/<run>/
r.json log-ppl matrix, CL metrics, exact command
r.generations.jsonl answers after phase 5
r.generations_phase<k>.jsonl answers after phase k+1 (k = 0..4)
r.generations_phase<k>.scores.json
r_phase<k>.memory.pt memory after phase k+1 (k = 0..4)
logs/ run logs
Checkpoint sizes: ~120 MB (Llama) / ~150 MB (Qwen) at 1024 slots, ~1.9 GB / ~2.4 GB at
16384. Resume with run_continual.py --resume-from <run>/r_phase<k>.memory.pt.
- Downloads last month
- 81